2204
P. Vízcaíno-Milla et al.
Special Topic
Synthesis
13C NMR: δ = 162.94, 158.03, 110.46, 57.67, 55.97, 35.02, 32.74, 25.27,
25.19.
(R)-2-(1-Benzyl-2,5-dioxopyrrolidin-3-yl)-2-methylpropanal
(9d)13b
HRMS (ES): m/z [M + H]+ calcd for C6H16N4: 193.1453; found:
Following the general procedure gave 9d (70.00 mg, 90%) as colorless
prisms; 82% ee.
193.1448.
HPLC (Chiralpak AD-H, 210 nm, n-hexane–i-PrOH, 80:20, 1.0
mL/min): tR = 8.0 (minor), 17.0 min (major).
(R,R)-2-(Pyrimidin-2-ylamino)cyclohexaneamine (ent-8); Typical
Procedure
1H NMR: δ = 9.49 (s, 1 H), 7.39–7.27 (m, 5 H), 4.72–4.57 (m, 2 H), 3.03
(dd, J = 9.4, 5.4 Hz, 1 H), 2.82 (dd, J = 18.3, 9.4 Hz, 1 H), 2.45 (dd, J =
18.3, 5.4 Hz, 1 H), 1.17 (s, 3 H), 1.16 (s, 3 H).
Following the typical procedure using 5 (3.27 g, 15.25 mmol) gave
ent-8 (2.64 g, 71% overall yield) as a yellow solid.
13C NMR: δ = 202.81, 177.55, 175.48, 135.77, 128.83, 128.77, 128.10,
48.17, 45.05, 42.59, 31.60, 20.08, 19.23.
Substituted Succinimides 9; General Procedure
To a solution of 8 or ent-8 (0.03 mmol), maleimide (0.3 mmol), and
hexanedioic acid (0.03 mmol, 10% mol) in DMF–H2O (2:1, 0.6 mL) was
added the aldehyde (0.6 mmol) and the mixture was stirred at 0 °C
until completion of the reaction (TLC) (times are given in Scheme 2).
Then, aq 2 M HCl (10 mL) was added and the mixture was extracted
with EtOAc (3 ×10 mL). The combined organic phases were washed
with H2O (2 × 10 mL), dried (MgSO4), filtered, and evaporated (20
mbar). The resulting crude was purified by flash chromatography (n-
hexane–EtOAc) to afford adduct 9.
(R)-2-[1-(4-Bromophenyl)-2,5-dioxopyrrolidin-3-yl]-2-methyl-
propanal (9e)14
Following the general procedure gave 9e (68.07 mg, 70%) as colorless
prisms; 87% ee.
HPLC (Chiralpak OD-H, 230 nm, n-hexane–i-PrOH, 75:25, 0.9
mL/min): tR = 30.7 (minor), 52.3 min (major).
1H NMR: δ = 9.48 (s, 1 H), 7.65–7.50 (m, 2 H), 7.22–7.12 (m, 2 H), 3.10
(dd, J = 9.5, 5.5 Hz, 1 H), 2.96 (dd, J = 18.2, 9.5 Hz, 1 H), 2.61 (dd, J =
18.2, 5.5 Hz, 1 H), 1.35 (s, 3 H), 1.28 (s, 3 H).
13C NMR: δ = 202.80, 176.70, 174.51, 132.48, 130.94, 128.19, 122.70,
48.83, 45.12, 32.11, 20.62, 20.08.
Compound 9a was also prepared on a larger scale (starting from 0.5 g,
2.8 mmol of NPM). Isolation by recrystallization (hexane–EtOAc) led
to 0.531 g (75%) of the product that maintained the same optical puri-
ty.
(R)-2-(2,5-Dioxo-1-phenylpyrrolidin-3-yl)-2-methylpropanal
(R)-2-[1-(3-Chlorophenyl)-2,5-dioxopyrrolidin-3-yl]-2-methylpro-
(9a)13b
panal (9f)14
Following the general procedure gave 9a (68.43 mg, 93%) as colorless
Following the general procedure gave 9f (77.20 mg, 92%) as colorless
prisms.
prisms; 87% ee.
HPLC [Chiralpak OD-H, 230 nm, n-hexane–i-PrOH, 70:30, 0.9
mL/min): tR = 17.4 (minor), 22.7 min (major).
HPLC (Chiralcel OD-H, 210 nm, n-hexane–i-PrOH, 75:25, 0.6
mL/min): tR = 24.0 (minor), 28.1 min (major).
1H NMR: δ = 9.52 (s, 1 H), 7.52–7.35 (m, 3 H), 7.31–7.24 (m, 2 H), 3.15
(dd, J = 9.5, 5.5 Hz, 1 H), 2.98 (dd, J = 18.2, 9.5 Hz, 1 H), 2.62 (dd, J =
18.2, 5.5 Hz, 1 H), 1.33 (s, 3 H), 1.29 (s, 3 H).
1H NMR: δ = 9.48 (s, 1 H), 7.44–7.31 (m, 2 H), 7.21 (m, 2 H), 3.11 (dd,
J = 9.5, 5.5 Hz, 1 H), 2.96 (dd, J = 18.2, 9.5 Hz, 1 H), 2.65–2.57 (dd, J =
18.2, 9.5 Hz, 1 H), 1.35 (s, 3 H), 1.27 (s, 3 H).
13C NMR: δ = 202.82, 176.97, 174.85, 131.95, 129.31, 128.85, 126.66,
13C NMR: δ = 202.8, 176.6, 174.4, 134.7, 132.9, 130.2, 128.9, 126.9,
48.66, 45.16, 32.02, 20.44, 19.79.
124.8, 48.7, 45.0, 32.0, 20.5, 19.9.
(R)-2-(2,5-Dioxopyrrolidin-3-yl)-2-methylpropanal (9b)15b
(R)-2-[1-(4-Chlorophenyl)-2,5-dioxopyrrolidin-3-yl]-2-methylpro-
panal (9g)13b
Following the general procedure gave 9b (38.53 mg, 76%) as colorless
prisms; 76% ee.
Following the general procedure gave 9g (73.00 mg, 87%) as colorless
prisms; 86% ee.
HPLC (Chiralpak AD-H, 210 nm, n-hexane–i-PrOH, 85:15, 1.0
mL/min): tR = 27.5 (major), 38.6 min (minor).
1H NMR: δ = 9.49 (s, 1 H), 8.73 (br s, 1 H), 3.10 (dd, J = 9.4, 5.8 Hz, 1 H),
2.85 (dd, J = 18.4, 9.4 Hz, 1 H), 2.51 (dd, J = 18.4, 5.8 Hz, 1 H), 1.25 (s, 3
H), 1.23 (s, 3 H).
HPLC (Chiralcel OD-H, 210 nm, n-hexane–i-PrOH, 75:25, 0.9
mL/min): tR = 22.4 (minor), 37.1 min (major).
1H NMR: δ = 9.49 (s, 1 H), 7.48–7.41 (m, 2 H), 7.29–7.22 (m, 2 H), 3.12
(dd, J = 9.5, 5.4 Hz, 1 H), 2.98 (dd, J = 18.1, 9.5 Hz, 1 H), 2.62 (dd, J =
18.1, 5.4 Hz, 1 H), 1.36 (s, 3 H), 1.29 (s, 3 H).
13C NMR: δ = 202.9, 178.3, 176.2, 48.0, 46.3, 32.8, 20.1, 19.4.
13C NMR: δ = 202.8, 176.7, 174.6, 134.6, 130.4, 129.5, 127.9, 48.8, 45.1,
32.1, 20.6, 20.0.
(R)-2-Methyl-2-(1-methyl-2,5-dioxopyrrolidin-3-yl)propanal
(9c)13b
(R)-1-(2,5-Dioxo-1-phenylpyrrolidin-3-yl)cyclopentanecarbalde-
Following the general procedure gave 9c (45.61 mg, 83%) as a color-
less oil; 76% ee.
hyde (9h)14
Following the general procedure gave 9h (68.37 mg, 84%) as colorless
prisms; 89% ee.
HPLC (Chiralpak AS-H, 210 nm, n-hexane–i-PrOH, 80:20, 1.0
mL/min): tR = 15.6 (major),17.7 min (minor).
HPLC (Chiralcel OD-H, 210 nm, n-hexane–i-PrOH, 75:25, 0.5
mL/min): tR = 37.0 (minor), 49.9 min (major).
1H NMR: δ = 9.38 (s, 1 H), 7.50–7.44 (m, 2 H), 7.39 (m, 1 H), 7.33–7.28
(m, 2 H), 3.05 (dd, J = 9.6, 5.2 Hz, 1 H), 2.97 (dd, J = 17.6, 9.6 Hz, 1 H),
2.59 (dd, J = 17.6, 5.2 Hz, 1 H), 2.36–1.73 (m, 8 H).
1H NMR: δ = 9.51 (s, 1 H), 3.04 (dd, J = 9.3, 5.4 Hz, 1 H), 2.99 (s, 3 H),
2.82 (dd, J = 18.2, 9.3 Hz, 1 H), 1.22 (s, 3 H), 1.21 (s, 3 H).
13C NMR: δ = 202.9, 177.7, 175.8, 48.1, 45.1, 31.6, 24.9, 20.1, 19.1.
© Georg Thieme Verlag Stuttgart · New York — Synthesis 2015, 47, 2199–2206